BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea
BioMarin reached a global settlement with Ascendis Pharma that ends all pending patent proceedings and gives BioMarin royalties on Yuviwel sales in the U.S., EU, Brazil and South Korea. The agreement removes a legal overhang for BMRN, but the specific royalty rates and expected financial contribution remain undisclosed, leaving the market without enough detail for a strong earnings read.
PR NEWSWIRE / FILEThe story
BioMarin announced Aug. 30 that it entered binding terms with Ascendis Pharma A/S to resolve all pending patent-related proceedings between the companies. Under the agreement, Ascendis will pay BioMarin royalties tied to Yuviwel sales in the U.S., EU, Brazil and South Korea.
The settlement changes the status of a dispute that had left the commercial and legal outlook for Yuviwel subject to patent proceedings. Instead of continuing across the affected markets, the matter will be governed by the agreed royalty arrangement. The specific royalty rates, payment timing, sales milestones and revenue estimates remain confidential.
For BioMarin, the direct connection is to future royalty revenue rather than the company's existing product sales. The company reported FY 2025 revenue of $3.2B, up 12.9% YoY, along with a 10.8% net margin and $1.80 diluted EPS. How the Yuviwel payments will affect those figures is unclear.
Ascendis is the commercial party responsible for Yuviwel sales in the four named territories, while BioMarin receives the contractual royalty stream. The patent claims covered, the duration of the royalties, the settlement's accounting treatment and any restrictions on commercialization have not been specified.
The missing detail limits the immediate financial interpretation. The agreement resolves the proceedings, but the size and timing of the economic benefit remain unclear. The next useful disclosures would be the complete settlement terms, BioMarin's treatment of the royalties in guidance or filings, and reported Yuviwel sales in the U.S., EU, Brazil and South Korea. Until those figures are available, the settlement is a clearer legal outcome than an earnings estimate.
Our read · Mon, Aug 31
The settlement removes patent uncertainty and adds an undisclosed royalty stream, modestly improving the setup for BMRN without yet changing the earnings case.
Why. The immediate consequence is a cleaner legal path and potential incremental revenue for BMRN, but the economic value cannot be sized because the release omits royalty rates, timing and Yuviwel sales. That makes the read constructive but insufficiently quantified for a conviction trade.
Both cases
What could change this view: The settlement could have limited royalty economics, and the absent terms may fail to improve BioMarin’s reported revenue or earnings materially.
Who reported it · 2
Keep reading
Latest on the Wire
Bitcoin nears $64,000 as Anthropic IPO lifts Nasdaq futures nearly 2%UniCredit reaches agreement with Berlin over Commerzbank takeoverAustralia’s jobless rate hits 5-year high, markets ramp up rate-cut bets for 2027Trump meets Putin and Xi separately ahead of historic three-way talksHyperscale Data warns of $74.8 million gap for Michigan AI projectContinue on the Wire →Latest on the Wire
Hyperscale Data warns of $74.8 million gap for Michigan AI projectMeta pauses plan to give Zuckerberg new shares without losing controlFed releases October meeting minutes three weeks after policy decisionAnthropic Said to Guide IPO Pricing Above Market RangeContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookNvidia interim CEO Colette Kress faces first earnings test after HuangNvidia CEO Jensen Huang reportedly resigns as US-China tensions riseNvidia CFO Colette Kress to serve as interim CEO after Jensen HuangAbout this report
Reported by PR Newswire, . Who answers for this
2 reports from 2 publishers in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →